Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Westvac Biopharma Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner in 1 art unit, creating a single prosecution path.
DUFFY, PATRICIA ANN is the listed examiner and handles the pending matter. The profile supports a focused response strategy built around the examiner’s treatment of the claims and the issues in that file.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833626 | METHOD FOR INDUSTRIAL PRODUCTION OF VACCINE AGAINST PSEUDOMONAS AERUGINOSA | DUFFY, PATRICIA ANN | — |
| 17923303 | ANTI- SARS-COV-2-INFECTION PROTEIN AND VACCINE | ALAM, DANYAL HASSAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833626 | METHOD FOR INDUSTRIAL PRODUCTION OF VACCINE AGAINST PSEUDOMONAS AERUGINOSA | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833626 | METHOD FOR INDUSTRIAL PRODUCTION OF VACCINE AGAINST PSEUDOMONAS AERUGINOSA | DUFFY, PATRICIA ANN | 1645 | §103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 17923303 | ANTI- SARS-COV-2-INFECTION PROTEIN AND VACCINE | ALAM, DANYAL HASSAN | 1672 | §101§102§103§112Other | Non-Final OA | — | Pending | Nov 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWestvac Biopharma Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Patricia Ann Duffy has the most, with 1 of Westvac Biopharma Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
